Open in interactive viewer → charts, metric popovers & call review

KORU Medical: The Trough Arrived On Schedule. The Oncology Story Quietly Left The Room.

A 500-basis-point margin gain and a guidance raise now carry a story that used to be carried by a $140 million oncology TAM — which management just put into a six-month cone of silence.
KRMD · Earnings Call · 2026-11-10

KORU Medical: The Trough Arrived On Schedule. The Oncology Story Quietly Left The Room.

A trough that was pre-announced, and a margin nobody pre-announced

KORU's Q3 is the rare quarter where the headline number is the least interesting thing in it. Revenue of $11.6 million, up 11%, is a deceleration from the 17% year-to-date pace, and the CFO was almost apologetic about it: “as Q3, as we mentioned in the last call, was sort of our trough” — Tom Adams, Chief Financial Officer · 2026-11-10. The optics are worse than the economics, because the prior-year quarter carried roughly $1.2 million of cross-geography distributor purchasing — the same onetime distributor impacts that management promised a year ago would never recur. On a normalized basis management reports domestic core +10% against a U.S. SCIg market growing 8–10%, and international core +23%. The distortion is in the base, not in the business. What wasn't pre-announced is the margin. Gross margin hit 65.2%, up 500 basis points year-over-year, and management attributes it to three things that are structural rather than lucky: throughput in manufacturing, a renegotiated CMO supply agreement that locks volume-based pricing, and favorable geographic mix toward higher-priced markets. That is the piece the filed numbers hadn't yet caught up with — the last reported quarter showed gross margin of 61.5% and a net margin of −6.9%. The gross-margin series has flipped from a multi-year decline into a three-year climb, and net profitability moved from deep negative to essentially zero. That is why the guide went up across all three axes simultaneously — “we're raising the bottom end of our full year guidance to $48 million to $48.5 million, representing 17% to 18% growth for the year” — Tom Adams, Chief Financial Officer · 2026-11-10 — with gross margin lifted to 63–64% and a year-end cash target above $8 million. Operating expenses fell from 70.2% of sales to 64% year-to-date. The company has quietly become a margin story wearing a growth story's clothes.

What KORU stopped talking about

Here is the real event of this report. Two quarters ago, oncology was the entire forward narrative: the Phesgo pivot, a $40 million market "growing over the next five years to over $120 million" in Q1, revised upward in Q2 to "about $60 million as we look at that total TAM today, continuing to grow over the next 4-5 years to upwards of $140 million." A TAM that ratchets 50% in a quarter is a TAM being sold. On this call, the analyst asked directly what management has most confidence in for 2027, and the answer was a hedge followed by a door closing: “we're not going to comment on oncology until kind of the first half of '27. So I'm going to hold off on that.” — Adam Kalbermatten, President and Chief Executive Officer · 2026-11-10 The keyword trail confirms it. Oncology market and Phesgo were live, ranked themes in the prior quarter's vocabulary; in the current quarter's top-30 they are simply gone — no replacement, no downgrade, just absence. The same is true of the infusion clinic channel, which was the number-one theme three quarters ago when RYSTIGGO was pitched as KORU's wedge into ambulatory oncology infusion. Today RYSTIGGO is described in an entirely different register — three U.S. specialty pharmacies dispensing for the home administration of RYSTIGGO, two using the complete system, one only the needle set. That is a good commercial fact and a much smaller claim than the one it replaced. The silence has a logic, and management states it plainly:

Many involve multibillion-dollar drug assets and these opportunities are highly competitive. As a result, I will only share further detail when our pharma partners are prepared to disclose more information publicly or when we have launched a commercial partnership.

Adam Kalbermatten, President and Chief Executive Officer · 2026-11-10
Fair enough — but it means the stock's largest optionality leg now has no disclosed milestone until the first half of 2027. What's left on the near calendar is smaller and more concrete: the deferoxamine 510(k) under FDA review ("clearance could come in the near term"), the Freedom360 regulatory filing due by year-end with approval presumably in the back half of 2027, an enzyme-replacement program dosing patients in Phase III (~5,000 patients), and a nephrology follow-on statement of work heading toward Phase III (~10,000 patients). Those are real, but they are single-digit-million-dollar events, not the oncology re-rating.

The geography engine finally has plumbing

If oncology went quiet, international went loud — and the language changed. For several quarters the international story was tender-driven: win the pharma tender, win the device volumes. This quarter introduces a genuinely new vocabulary word, nontender market, and with it a different growth mechanic — account by account, home care company by home care company, rather than one catalytic award. The proof points: “we signed the distribution and sales agreement with a pan-European supplier... a partner we're working with across multiple different geographies in Europe” — Adam Kalbermatten, President and Chief Executive Officer · 2026-11-10, chosen specifically because it spans wholesaler, home care provider and pharmacy, plus a first distribution agreement in Africa with an initial order already shipped. CEO Adam Kalbermatten puts current European share at roughly 20% against a much higher U.S. position — the gap is the thesis. The critical dependency remains new patient starts, and on that the CEO is explicit that the SCIg market is doing the heavy lifting: "it was in the range of 1.8% to 2% quarter-on-quarter... year-on-year continuing to grow kind of around that 8% to 10%." KORU's job is outperformance, not category creation. Asked whether the old rule-of-thumb — U.S. core 10–15%, international 20–30% — still holds for 2027, the answer was an oblique yes: “you're on the right track there with how we see it” — Adam Kalbermatten, President and Chief Executive Officer · 2026-11-10, wrapped in the same budgeting process deferral that has become a recurring feature of these calls.

The tape versus the text

The stock is not priced for the margin story. Shares are down 12% over 90 days, having fallen 34% across eleven weeks before bouncing 29% in the five weeks into this print — a position-and-hope setup, not a de-risked one. At a $179 million market cap and roughly 4.6x revenue, the valuation has round-tripped most of its post-2020 premium while retaining a pipeline premium that the company has just told you it won't discuss until mid-2027. The balance sheet supports the waiting: $7.4 million of cash, an undrawn $10 million facility, and an effective net cash position that has stabilized after two years of decline. Cash usage of $900,000 in the quarter was working capital — inventory pre-build for Q4 and a higher receivables balance — which is a reasonably honest tell that management believes its own fourth-quarter acceleration. So the trade is now legible, if not exciting: you own a near-breakeven, 17%-growing, 65%-gross-margin consumables annuity that is funding its own optionality, and you are being asked to wait through a self-imposed information blackout on the one program that could change the multiple. The bull case needs only two things to go right in the next twelve months — a deferoxamine clearance and a Freedom360 approval — and one thing to go unsaid: oncology. Investors should note which of those management chose to narrate this quarter, and which they chose not to.